Synthon, Goldman Sachs and BC Partners
BC Partners agrees to sell majority stake in Synthon to Goldman Sachs Alternatives
BC Partners has agreed to sell its majority stake in Synthon to Goldman Sachs Alternatives. Synthon is an international pharmaceutical company, with a platform specialized in developing, manufacturing, and out-licensing complex generic medicines.
Goldman Sachs’ investment arm agrees €2bn deal for drugmaker Synthon
Goldman Sachs Asset Management has agreed a more than €2bn deal to acquire drugmaker Synthon from BC Partners, according to people familiar with the matter, as it hopes to capitalise on demand for off-patent versions of complex medicines.
Goldman Sachs’ asset arm is in the process of acquiring the Dutch pharmaceutical company Synthon International for 2 billion ...
Byondis began life as Synthon Biopharmaceuticals, an affiliate of generics company Synthon. The affiliate initially focused on biosimilars and later on innovative biologics and small molecules.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback